International nonproprietary names for biological and biotechnological drugs
Abstract
The article presents generalized information about the program of the World Health Organization (WHO) related to International Nonproprietary Names (INN) of biological and biotechnological drugs. It reflects general principles for selecting INN for biological and biotechnological preparations, immunoglobulins (sera), preparations for gene therapy, glycosylated proteins and peptides, non-glycosylated proteins peptides and proteins, hybrid proteins, blood preparations, monoclonal antibodies, skin substitutes, transgenic products, vaccines, biosimilars. The conclusion was made about the need for an early solution to the global problem of assigning INN to biological and biotechnological drugs, while the number of authorized products remains relatively small.
About the Authors
V. V. Dudchenko
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
P. I. Popov
People's Friendship University of Russia
Russian Federation
Russian Federation
N. D. Bunyatyan
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. N. Yavorsky
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. A. Merkulov
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Guidelines on use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. WHO/PHARM S/Nom 1570. Geneva: WHO; 1997.
2. International Nonproprietary Names: revised procedure. Procedure for the selection of recommended international nonproprietary names for pharmaceutical substances. EB115.R4. Geneva: WHO; 2005.
3. WHO/EMP/RHT/TSN/2013.1. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. 2013.
4. WHO International Nonproprietary Names (INN) for Biological and Biotechnological Substances. A Review. Programme on International Nonproprietary Names (INN). Quality Assurance and Safety: Medicines (QSM). Medicines Policy and Standards (PSM) Department.
5. Vasiliev AN, Gavrishina EV, Niyazov RR, Snegireva AA, Adonin VK. Introduction to the European legislation on medicines. Biological medicines. Remedium 2013; (9): 49–54 (in Russian).
6. Vasiliev AN, Niyazov RR, Engalycheva GN, Gavrishina EV, Tuter EA, Bekerman AN. Confirmation of the quality, preclinical and clinical studies of similar biological medicinal products. General principles. Remedium 2013; (6): 22–26 (in Russian).
7. Niyazov RR, Goryachev DV, Gavrishina EV, Romodanovskiy DP, Dranitsyna MA. Justification of the borders of the equivalence of indicators of quality, safety and efficiency in the development of biosimilars. Eksperimentalnaya i klinicheskaya farmakologiya 2015; 78(6): 37–44 (in Russian).
8. Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Safety monitoring of medicines. Bezopasnost i risk farmakoterapii 2014; 3(4): 11–14 (in Russian).
9. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. U.S. Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm.
10. Vasiliev AN, Gavrishina EV, Niyazov RR, Dobrovolskiy AV, Tuter EA, Bekerman AN. Biologically similar drugs in the Russian Federation and prospects of their development. Remedium 2013; (7–8): 67–70 (in Russian).
Review
For citations:
Dudchenko V.V., Popov P.I., Bunyatyan N.D., Yavorsky A.N., Merkulov V.A. International nonproprietary names for biological and biotechnological drugs. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):32-38. (In Russ.)
Views:
838
Email this article 